FDA Approval in Liposarcoma, Breakthrough Designations in mCRPC and AML, and More

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.

Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.

Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.

The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.

Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.

Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.

Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.